Compounds and methods for the modulation of kinases and indications for this

A compound of formula (Ig-2): ** Formula ** wherein R15 is cyclopropyl; Y 2 is H, halogen, CN, C 1-5 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C 3-8 cycloalkylC 0-4 alkyl or (R 2) (R 3) N-, wherein R 2 and R 3 are each independently selected from the group consisting of H, C 1-6 alkyl, C 1-6 alkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C 3-8 cycloalkyl-C 4-4 alkyl, heterocycloalkyl and heterocycloalkyl C 1-4 alkyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form a ring of three to eight members having 0-2 additional heteroatoms as selected ring members of N, O or S; wherein Y2 is optionally substituted with one to three groups independently selected from Re; Q is selected from H, F, Cl or CH3; R 11 is C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or Re; the subscript m is an integer from 0 to 3; the subscript n is an integer from 1 to 5; and Re is selected from the group consisting of halogen, -CH = CH2, -CN, -OH, -NH2, -NO2, -C (O) OH, -C (S) OH, -C (O) NH2, - C (S) NH2, -S (O) 2NH2, -NHC (O) NH2, -NHC (S) NH2, -NHS (O) 2NH2, -C (NH) NH2, -ORf, -SRf, -OC ( O) Rf, -OC (S) Rf, -C (O) Rf, -C (S) Rf, -C (O) ORf, -C (S) ORf, -S (O) Rf, -S (O ) 2Rf, -C (O) NHRf, -C (S) NHRf, -C (O) NRfRf, -C (S) NRfRf, -S (O) 2NHRf, -S (O) 2NRfRf, -C (NH) NHRf, -C (NH) NRfRf, -NHC (O) Rf, -NHC (S) Rf, -NRfC (O) Rf, -NRfC (S) Rf, -NHS (O) 2Rf, -NRfS (O) 2Rf , -NHC (O) NHRf, -NHC (S) NHRf, -NRfC (O) NH2, -NRfC (S) NH2, -NRfC (O) NHRf, -NRfC (S) NHRf, -NHC (O) NRfRf, -NHC (S) NRfRf, -NRfC (O) NRfRf, -NRfC (S) NRfRf, -NHS (O) 2NHRf, -NRfS (O) 2NH2, -NRfS (O) 2NHRf, -NHS (O) 2NRfRf, - NRfS (O) 2 NRfRf, -NHRf, -NRfRf and Rf, wherein Rf is C 1-6 alkyl or aryl; wherein cycloalkyl itself or as part of another substituent, refers to saturated or unsaturated, non-aromatic, monocyclic, bicyclic or tricyclic 3-8 membered ring systems in the ring; and heterocycloalkyl refers to a non-aromatic saturated or unsaturated cycloalkyl group containing one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom (s) are optionally quaternized, the remainder of the atoms of the C ring being, wherein one or two C atoms may optionally be replaced by a carbonyl; or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer or mixture of stereoisomers thereof.